A Single-Center 2-Arm Study for Lentigines on the Hands
Primary Purpose
Lentigines
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Enlighten Laser
Excel V Laser
Sponsored by
About this trial
This is an interventional treatment trial for Lentigines
Eligibility Criteria
Inclusion Criteria:
- Female or Male, 30-90 years of age (inclusive).
- Fitzpatrick Skin Type I - III.
- Desires non-invasive and non-ablative treatment of lentigines on the hand(s).
- Have 4 or more lentigines on the hand(s).
- Subject must be able to read, understand and sign the Informed Consent Form.
- Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
- Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period.
- Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
- Agree to not undergo any other procedure(s) for treatment of lentigines during the study, including but not limited to chemical peel, laser and light based device treatment, and home-use device treatment.
- Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler to the treatment area during the study.
Exclusion Criteria:
- Participation in a clinical trial of another device or drug in the target area within 6 months prior to enrollment or during the study.
- Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser or light-based procedures or surgery.
- Systemic use of retinoid, such as isotretinoin, within 6 months of study participation.
- Use of topical medications on the hands, such as antibiotics, benzoyl peroxide, retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing dihydroxyacetone or alpha-hydroxy with concentration > 8%, within 1 month of participation.
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
- Pregnant.
- Having an infection, dermatitis, or a rash in the treatment area.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- Any use of medication that is known to increase sensitivity to light according to investigator's discretion.
- History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
- History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
- Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systematic therapy that could interfere with this research study.
Sites / Locations
- DuPage Medical Group
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Enlighten Laser
Excel V Laser
Arm Description
12 subjects will receive treatment the Enlighten laser.
12 subjects will receive treatment with the Excel V laser.
Outcomes
Primary Outcome Measures
Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers.
Secondary Outcome Measures
Physician's Global Assessment Score of the Overall Appearance of the Hands
Degree of improvement in the overall appearance of the hands as assessed by blinded reviewers using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change Higher scores indicate better outcomes
Physician's Global Assessment Score of Skin Texture of the Hands
Degree of improvement in the Skin Texture of the hands as assessed using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change. Higher scores indicate better outcomes
Subject Satisfaction
Subject-completed questionnaire to rate their level of satisfaction with the laser treatment outcome
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02763072
Brief Title
A Single-Center 2-Arm Study for Lentigines on the Hands
Official Title
A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
June 26, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cutera Inc.
4. Oversight
Studies a U.S. FDA-regulated Device Product
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of two laser systems for improvement of lentigines on the hands.
Detailed Description
The purpose of this study is to evaluate the effectiveness and safety in a clinic setting of two laser systems for the treatment of lentigines (liver spots, age spots, or dark sun spots) on the hands.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lentigines
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Enlighten Laser
Arm Type
Experimental
Arm Description
12 subjects will receive treatment the Enlighten laser.
Arm Title
Excel V Laser
Arm Type
Active Comparator
Arm Description
12 subjects will receive treatment with the Excel V laser.
Intervention Type
Device
Intervention Name(s)
Enlighten Laser
Intervention Type
Device
Intervention Name(s)
Excel V Laser
Primary Outcome Measure Information:
Title
Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers.
Time Frame
4 weeks post-final treatment
Secondary Outcome Measure Information:
Title
Physician's Global Assessment Score of the Overall Appearance of the Hands
Description
Degree of improvement in the overall appearance of the hands as assessed by blinded reviewers using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change Higher scores indicate better outcomes
Time Frame
4 weeks post final treatment
Title
Physician's Global Assessment Score of Skin Texture of the Hands
Description
Degree of improvement in the Skin Texture of the hands as assessed using the Physician's Global Assessment scale: 4=Very Significant Improvement,3=Significant Improvement, 2=Moderate Improvement, 1=Mild Improvement and 0=No Change. Higher scores indicate better outcomes
Time Frame
4 weeks post final treatment
Title
Subject Satisfaction
Description
Subject-completed questionnaire to rate their level of satisfaction with the laser treatment outcome
Time Frame
4 weeks post final treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Female or Male, 30-90 years of age (inclusive).
Fitzpatrick Skin Type I - III.
Desires non-invasive and non-ablative treatment of lentigines on the hand(s).
Have 4 or more lentigines on the hand(s).
Subject must be able to read, understand and sign the Informed Consent Form.
Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period.
Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
Agree to not undergo any other procedure(s) for treatment of lentigines during the study, including but not limited to chemical peel, laser and light based device treatment, and home-use device treatment.
Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler to the treatment area during the study.
Exclusion Criteria:
Participation in a clinical trial of another device or drug in the target area within 6 months prior to enrollment or during the study.
Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser or light-based procedures or surgery.
Systemic use of retinoid, such as isotretinoin, within 6 months of study participation.
Use of topical medications on the hands, such as antibiotics, benzoyl peroxide, retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing dihydroxyacetone or alpha-hydroxy with concentration > 8%, within 1 month of participation.
History of malignant tumors in the target area.
Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
Pregnant.
Having an infection, dermatitis, or a rash in the treatment area.
History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
Any use of medication that is known to increase sensitivity to light according to investigator's discretion.
History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systematic therapy that could interfere with this research study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kelly Stankiewicz, MD FAAD
Organizational Affiliation
DuPage Medical Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
DuPage Medical Group
City
Naperville
State/Province
Illinois
ZIP/Postal Code
60563
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Single-Center 2-Arm Study for Lentigines on the Hands
We'll reach out to this number within 24 hrs